Baird analyst David Rescott lowered the firm’s price target on TransMedics (TMDX) to $140 from $157 and keeps an Outperform rating on the shares. The firm updated its model following Q1 results which missed estimates but where Baird said they remain buyers of the shares ahead of its long-term catalyst pathway.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TMDX:
- TransMedics Group: Buy Rating Reiterated as Transplant Volumes Support Growth; $190 Price Target Maintained
- TransMedics signs agreement to invest in PAD Aviation
- TransMedics Maintained at Buy as CHOPS Platform Broadens Transplant Offering; $152 Price Target Reiterated
- TransMedics: Strengthening Leadership in Organ Preservation Through Rigorous Clinical Trials and Normothermic Perfusion Evidence
- William Blair healthcare IT analysts hold analyst/industry conference call